BMA In Focus

BMACAPITAL

Monetary Policy Preview

No change expected as easing likely after elections

The State Bank of Pakistan (SBP)'s monetary policy committee will likely convene in late January or early February to set interest rates for the next six weeks. We anticipate the central bank will keep the policy rate unchanged at 22%, with our stance based on high inflation readings and the volatile geopolitical landscape.

Inflation readings are likely to remain high till February 2024: Inflation readings will likely remain elevated till February 2024 because of higher food and energy prices. Notably, the inflation trajectory was influenced by the impact of the gas price hike. Moreover, supply issues have caused sharp price hikes in many constituents of the food basket. The impact of these trends was evident in the most recent SPI reading, which saw weekly inflation figures cross the 44% mark.

Pakistan's inflation readings may slow down from March 2024: From March 2024, the high inflation base will kick in and bring real interest rates into positive territory. Notably, average monthly inflation for 2HFY24 may touch 22.1% against 28.8% registered during 1HFY24. With an absence of any inflationary catalysts on the horizon, we see monthly inflationary readings falling below the 20% mark by April 2024.


The geopolitical landscape is increasingly volatile: Recent weeks have seen the escalation of geopolitical volatility marked by conflicts in the Middle Eastern region. These conflicts have raised concerns about the potential disruption of global trade routes and its impact on global commodity prices. Oil prices have exhibited heightened volatility as investors weigh potential supply disruptions with demand concerns.

Pakistan is also embroiled in conflict with Iran, evident by cross-border skirmishes targeting militant groups. Recent developments, however, suggest that the escalation was a one-off event, and both countries are actively making efforts to de-escalate the situation. Investors, nevertheless, remain wary of potential delays in the general elections due to security concerns and the possible impact on Pakistan's investment climate, particularly in the context of the SIFC.


Global monetary easing cycles may also be pushed back: Sticky inflation amidst heightened geopolitical volatility has the potential to push back global monetary easing cycles. The US's recent monthly CPI reading (3.4%), which registered higher than industry expectations (3.2%), compelled many to revise their timelines of the US Fed's rate cut cycle. Late in December, investors had priced a 74% probability of a rate cut in March 2024's FOMC. The probability has now lowered to 54% after the country's CPI reading, robust economic data, and heightened geopolitical volatility.

Moreover, the EU region is also facing a reversal in its inflation trajectory, with recent figures rebounding after seven consecutive monthly declines. Conflicts at the Red Sea and the consequent disruption of trade routes can fuel the region's inflation and likely compel the ECB to push back the monetary easing cycle.


Sunday, January 21, 2024



Source: PBS, BMA Research



Source: Bloomberg, BMA Research



Source: US Fed, BMA Research

BMA Research

Tel: 111-262-111 Ext. 2056
E-mail: yousuf.rahman@bmacapital.com
BMA Capital Management Ltd.




External accounts largely under control: Pakistan's external accounts are largely under control, evident by subdued trade and current account imbalances. Notably, 1HFY24 saw the **trade deficit fall to 5.3% of GDP** as against 10.4% of GDP recorded back in FY22. Moreover, the country's **current account deficit (CAD) is registered at 0.4%** of GDP during 1HFY24 as against 4.7% of GDP recorded during FY22. Improvements in external accounts were largely driven by the general economic slowdown, limiting demand for imported commodities. Moreover, falling global commodity prices further supported the country's external imbalances.


Pak Rupee finding strength: The Pak Rupee has continued to gain ground over the past two months as the currency has appreciated below the 280 per USD mark, a level last seen back in October 2023. Materialization of US Dollar inflows amidst declining demand for the currency has caused the Pak Rupee to gain 3% of its value since November 2023. Moreover, administrative efforts to limit the outflow of US Dollars through illicit channels have further strengthened the currency's prospects. Notably, the Pak Rupee's REER has increased to 98.9 as of December 2023 compared with 85.6 witnessed back in April 2023.

The next few months may witness **REER inch past the 100 mark**, supported by US Dollar inflows and limited outflows. Onwards, however, we see the Pak Rupee depreciating as the monetary easing cycle commences and economic activity picks pace. The currency **may touch 300 per USD by June 2024 and 320 per USD by December 2024.**

Secondary market yields on the decline: Over the past month, short-term yields have declined by 70bps, and longer-tenor yields are down by 60bps. The decline in yields indicates an expectation of an eventual monetary easing cycle as **short-term yields are trading around 170bps below** the prevalent policy rate. Moreover, trends witnessed in recent treasury auctions further substantiate the market's expectation of an eventual easing as the bulk of the bids has been tilted toward longer tenor securities.



Source: SBP, BMA Research



Source: SBP, BMA Research



Source: SBP, BMA Research



Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

Old rating system

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)